Sai Life Science Live Share Price Today, Share Analysis and Chart

About the company - Business Profile

Sai Life Sciences Ltd. is a full-service Contract Research, Development, and Manufacturing Organization (CRDMO) that supports global pharmaceutical and biotechnology innovators. The company provides a comprehensive platform across the drug discovery, development, and commercial manufacturing value chain for New Chemical Entities (NCE). As of 2025, the company maintains relationships with 18 of the top 25 global pharmaceutical firms and serves over 300 active customers across the US, UK, Europe, and Japan. Its operations are strategically balanced between innovation-focused research laboratories in global hubs and cost-efficient, large-scale manufacturing facilities in India.

Key Points

• Key Facts: Founded in 1999 and headquartered in Hyderabad, India, Sai Life Sciences successfully listed on the BSE and NSE on December 18, 2024. The IPO was subscribed 10.27 times, reflecting significant investor interest.
• Operations and Resources:
  • Facilities: Operates an integrated R&D campus spanning 13 acres in Genome Valley, Hyderabad. Manufacturing operations are primarily located in Bidar, Karnataka, with a current reactor capacity of 700 KL. Overseas facilities include an exploratory biology lab in Boston, US, and a process R&D lab in Manchester, UK.
  • Expansion: The company is scaling its reactor capacity from 700 KL to 1,150 KL by 2026. A new CMC Process R&D Block in Hyderabad, scheduled for completion by September 2026, is expected to double its current process R&D capacity.
• Business Model: Sai Life Sciences operates an integrated CRDMO model. It is particularly effective at transitioning molecules from the discovery phase (Hit to IND) to commercial production. As of March 2025, it had 30 commercial molecules and 6 molecules in Phase III or pre-registration.
• Financial Performance (FY25 Annual):
  • Revenue from Operations: ₹1,695 crore.
  • EBITDA: ₹425 crore (25% margin).
  • Profit After Tax (PAT): ₹170 crore.
  • H1FY26 Performance: Revenue grew to ₹1,034 crore for the first half of FY26, with an EBITDA of ₹281 crore and PAT of ₹144 crore.
• Segment and Geographic Insights:
  • Discovery Services (CRO): This segment has shown a CAGR of 35% from FY21 to FY25. Over 65% of discovery revenue comes from customers utilizing multiple services.
  • Geographic Focus: The primary customer base is located in regulated markets, including the US, UK, and EU. The company is positioning itself to benefit from the "China-to-India" outsourcing shift in the global CRDMO market.
• Technology and Innovation:
  • Specialized Modalities: Capabilities include high-potency APIs, peptides, and amidites.
  • Digital Transformation: Implementation of integrated e-systems like LIMS (Laboratory Information Management System) and e-QMS. The company aims for full digitization of operations by 2027, incorporating AI/ML models for manufacturing process prediction.
• Employee Base: The company employs over 3,400 personnel, of which 2,605 are scientists. This high concentration of scientific talent (approx. 76% of the workforce) supports its research-led business model.
• Sustainability: Sai Life Sciences is the first Indian company to join the Pharmaceutical Supply Chain Initiative (PSCI). The Bidar manufacturing site utilizes 89% renewable energy, and the company maintains a Zero Liquid Discharge (ZLD) status for water-neutral operations.

References

1. Annual Report May 2025
2. Investor Presentation Nov 2025
3. Investor Presentation Feb 2026